SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.15-0.3%Nov 3 1:15 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg9/23/2008 7:01:27 AM
  Read Replies (1) of 2240
 
There were som interesting points that were brought up at yesterday's UBS Presentation (Pien).

J&J royalties.
Pien, for the first time to my knowledge, gave an indication what royalties that may be expected from the two mAbs, which are now abut to be approved.

Name        mAb           peak turnover    peak royalties
cto 1275    ustekinumab   1.800 mUSD       50 mUSD 
cnto 148    golimumab     2.800 mUSD       90 mUSD

Survival - late responders
According to Pien, the survival curve for late responders (after 24 weeks) in the three phase II trials are similar to the one for patients who responded within 24 weeks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News